Teriparatide, a synthetic form of parathyroid hormone (PTH), helps treat osteoporosis by:

1. Stimulating Bone Formation: Teriparatide activates osteoblasts (bone-building cells), increasing bone formation, particularly in trabecular bone (spongy bone tissue).
2. Increasing Bone Density: It significantly improves bone mineral density (BMD), especially in the spine and hip, reducing the risk of fractures.
3. Enhancing Bone Microarchitecture: It improves bone quality by increasing connectivity and thickness of bone trabeculae, making bones stronger.
4. Reducing Fracture Risk: Clinical studies show teriparatide reduces vertebral fractures by up to 65% and non-vertebral fractures by about 53% in postmenopausal women with osteoporosis.
5. Promoting Bone Remodeling: It enhances the bone remodeling process, favoring bone formation over resorption when used intermittently (daily injections).

Teriparatide is typically prescribed for severe osteoporosis or when other treatments fail, administered as a daily subcutaneous injection for up to 2 years due to safety concerns with prolonged use. It’s particularly effective in postmenopausal women, men with osteoporosis, and those with glucocorticoid-induced osteoporosis.

Disclaimer: Owerl is not a doctor; please consult one.